Scripps Clinical Hematology and Oncology 2025

+ Include: 41 videos + 1 pdf, size: 22.73 GB

+ Target Audience: hematologists, oncologists, internists, advanced practice providers, and trainees

+ Information:

Clinical Hematology & Oncology Presented by Scripps Cancer Center

FEBRUARY 15-17, 2025 Hyatt Regency La Jolla at Aventine • San Diego, CA

The Scripps Cancer Center’s Clinical Hematology and Oncology conference is designed for hematologists, oncologists, surgeons, radiation oncologists, internists, and others desiring an update in these specialty areas. The primary objective of this course is to bring together clinicians and leading experts in diverse areas of hematology and oncology, affording them an intimate environment in which to discuss new clinical developments and significant advances. Our annual program is a nationally accredited continuing medical education conference and is one of the largest annual hematology/oncology meeting held in the West, among others such as ASH, ASCO and the San Antonio Breast Meeting. This conference is one of the few that combines topics in both hematology and oncology.

Educational Objectives

After attending this live activity, participants should be able to:

• Describe the clinical and molecular facets of pathogenesis, diagnostic approaches, and therapeutic modalities available for various hematologic disorders.
• Select and apply the changing approaches to hematologic malignancies, particularly as they relate to evidence-based standards of care, including innovations in diagnosis and treatment.
• Choose new therapeutic options for the treatment of several common malignancies, understanding appropriate indications and contraindications to these therapeutic approaches.
• Integrate evolving approaches to solid tumors and breast cancer from both a diagnostic, prognostic, and therapeutic perspective.
• Apply practical expertise gained from the clinical situations discussed in the panel sessions with an emphasis on data-based approaches to patients with common, but serious hematology oncology conditions.

The Scripps Clinical Hematology and Oncology Conference 2025 is best for hematologists, oncologists, internists, advanced practice providers, and trainees who want CME‑accredited, expert‑led updates on the latest therapies, diagnostics, and multidisciplinary management strategies in cancer and blood disorders.

 Who Should Attend

• Medical oncologists and hematologists managing patients with solid tumors, leukemias, lymphomas, and other blood disorders.
• Internal medicine physicians and subspecialists who co‑manage cancer patients or encounter hematologic issues in practice.
• Advanced practice providers (NPs, PAs, CNSs) working in oncology and hematology clinics.
• Residents and fellows in hematology/oncology training programs preparing for board exams or subspecialty practice.
• Oncology nurses and pharmacists involved in cancer care delivery and supportive therapy.

 What You’ll Learn

• Latest clinical trial data and FDA approvals in hematology and oncology.
• Updates in immunotherapy, targeted therapy, and cellular therapies (CAR‑T, bispecifics).
• Best practices in supportive care: symptom management, survivorship, and toxicity mitigation.
• Multidisciplinary approaches to cancer care, integrating surgery, radiation, and systemic therapy.
• Case‑based discussions highlighting diagnostic and therapeutic challenges.

 

+ Topics:

Saturday, February 15, 2025

• 7 a.m. Registration, Breakfast & View Exhibits
• 7 a.m. Non-CME Breakfast Symposium Hosted by Pfizer
• 7:55 a.m. Welcome & Educational Overview
• 8 a.m. Peri-operative Thrombocytopenia Ted Warkentin, MD
• 8:30 a.m. Hormonal Therapy and Thrombosis Risk Damon Houghton, MD
• 9 a.m. Barely Abnormal CBCs Alice Ma, MD
• 9:30 a.m. Panel Discussion/Q&A
• 10 a.m. Break & View Exhibits
• 10:15 a.m. Antiphospholipid Syndrome: 2024 Update Stephan Moll, MD
• 10:45 a.m. Hypereosinophilic Syndrome Jason Gotlib, MD
• 11:15 a.m. Investigating Bleeding of an Obscure Cause Menaka Pai, MD
• 11:45 a.m. Panel Discussion/Q&A
• Noon Lunch Noon Non-CME Lunch Symposium Hosted by Agios Pharmaceuticals Noon Non-CME Lunch Symposium Hosted by AstraZeneca
• 1 p.m. What’s New in AML TBD
• 1:30 p.m. Should Patients Still Undergo BMT for Myeloma? Morie Gertz, MD
• 2 p.m. Evolving Therapeutic Approaches in Patients with Low-risk MDS Aref Al-Kali, MD
• 2:30 p.m. Panel Discussion/Q&A
• 2:45 p.m. Break & View Exhibits
• 3:15 p.m. Clinical Updates in B-ALL Wendy Stock, MD
• 3:45 p.m. Refractory Diffuse Large Cell Lymphoma Stephen Schuster, MD
• 4:15 p.m. HLH and HLH-like Inflammatory Syndromes TBD
• 4:45 p.m. Panel Discussion/Q&A
• CONCURRENT BREAKOUT SESSIONS 5:15 p.m.
  • Breakout #1: Interesting Cases in Thrombosis Stephan Moll, MD
  • Breakout #2: Interesting Cases in Thrombocytopenia Ted Warkentin, MD
  • Breakout #3: Interesting Cases in Bleeding Alice Ma, MD
  • Breakout #4: Interesting Cases in Plasma Cell Dyscrasias Morie Gertz, MD
• 6:15 p.m. Adjourn

Sunday, February 16, 2025

• 7 a.m. Breakfast & View Exhibits
• 7 a.m. Non-CME Breakfast Symposium Hosted by Pfizer
• 7:55 a.m. Welcome & Announcements
• 8 a.m. Ultra Low Her2 Breast Cancer: Pushing the Boundary in IHC 0 and Treatment Implications TBD
• 8:30 a.m. Changing Landscape of Sequencing in HR Positive, Her2 Negative Metastatic Breast Cancer Aditya Bardia, MD
• 9 a.m. Sequencing Therapies in Early Triple Negative Breast Cancer Laura Huppert, MD
• 9:30 a.m. Panel Discussion/Q&A
• 10 a.m. Break & View Exhibits
• 10:30 a.m. Neoadjuvant and Adjuvant Therapy for Melanoma TBD
• 11 a.m. Management of Variant Histology Renal Cell Carcinoma Sumanta Pal, MD
• 11:30 a.m. Targeted Therapies in Central Nervous System Metastasis TBD
• Noon Panel Discussion/Q&A
• 12:30 p.m. Lunch
• 12:30 p.m. Non-CME Lunch Symposium Hosted by Lilly
• 1:30 p.m. Rectal Cancer—Making Sense of TNT, ctDNA, and Surgery: A Case-based, Multidisciplinary Discussion Michael Overman, MD—Medical Oncology Brian Bednarski, MD—Rectal Surgery Eugene Koay, MD—Radiation Oncology
• 3 p.m. Panel Discussion/Q&A
• 3:30 p.m. Break & View Exhibits
• 4 p.m. New Targeted Therapies for Gastroesophageal Cancer TBD
• 4:30 p.m. Updates in Neuroendocrine Tumors Jonathan Strosberg, MD
• 5 p.m. Panel Discussion/Q&A
• 5:30 p.m. Adjourn

Monday, February 17, 2025

• 7 a.m. Breakfast & View Exhibits
• 7:55 a.m. Welcome & Announcements
• 8 a.m. Role of Immune Therapy in Advanced Endometrial Cancer Ramez Eskander, MD
• 8:30 a.m. Updates in the Treatment of Metastatic Soft Tissue Sarcoma Mark Agulnik, MD
• 9 a.m. Genomic Risk Stratification and High Sensitivity Imaging in Localized Prostate Cancer Tanya Barauskas Dorff, MD
• 9:30 a.m. Panel Discussion/Q&A
• 10 a.m. Break & View Exhibits
• 10:30 a.m. Optimal Management of ALK Rearranged NSCLC Kamya Sankar, MD
• 11 a.m. Evidence-Based Management of Hormone Deprivation Symptoms After Cancer TBD
• 11:30 a.m. Management of Common Skin-related Side Effects of Cancer Treatment TBD
• Noon Panel Discussion/Q&A
• 12:30 p.m. Final Adjournment Topics, times, and speakers are subject to change.